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Abstract:  Angiogenesis, the process of new blood vessel formation, is implicated in 
various physiological/pathological conditions, including embryonic development, 
inflammation and tumor growth. Fibroblast growth factor-2 (FGF2) is a heparin-binding 
angiogenic growth factor involved in various physiopathological processes, including 
tumor neovascularization. Accordingly, FGF2 is considered a target for antiangiogenic 
therapies. Thus, numerous natural/synthetic compounds have been tested for their capacity 
to bind and sequester FGF2 in the extracellular environment preventing its interaction with 
cellular receptors. We have exploited surface plasmon resonance (SPR) technique in search 
for antiangiogenic FGF2 binders/antagonists. In this review we will summarize our 
experience in SPR-based angiogenesis research, with the aim to validate SPR as a first line 
screening for the identification of antiangiogenic compounds. 
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1. The Angiogenesis Process 
Angiogenesis, the process of new blood vessel formation from pre-existing ones, plays a key role in 
various physiological and pathological conditions, including embryonic development, wound repair, 
inflammation, and tumor growth [1]. The local, uncontrolled release of angiogenic growth factors 
(AGFs) and/or alterations of the production of natural angiogenic inhibitors, with a consequent 
alteration of the angiogenic balance, are responsible for the uncontrolled endothelial cell (EC) 
proliferation that takes place during tumor neovascularization and angiogenesis-dependent diseases 
[2]. 
The 1980s saw for the first time the purification to homogeneity of pro-angiogenic proteins, the 
breakthrough coming as a result of the observation that EC growth factors showed a marked affinity 
for heparin [3,4]. This lead to the identification, purification, and sequencing of the two prototypic 
heparin-binding angiogenic fibroblast growth factors (FGF) 1 and 2. Since then, numerous inducers of 
angiogenesis have been identified, including the members of the vascular endothelial growth factor 
(VEGF) family, angiopoietins, transforming growth factor- and - (TGF- and TGF-), platelet-
derived growth factor (PDGF), hepatocyte growth factor (HGF), tumor necrosis factor- (TNF-), 
interleukins (ILs), and chemokines [5]. 
Angiogenesis is a multi-step process that begins with the degradation of the basement membrane by 
activated ECs that will then migrate and proliferate, leading to the formation of solid EC sprouts into 
the stromal space. Later, EC sprouts undergo a morpho-functional rearrangement, giving origin to a 
functional capillary (Figure 1).  
Accordingly, AGFs induce a complex “pro-angiogenic phenotype” in cultured ECs that 
recapitulates the neovascularization process, including production of proteases that degrade the 
extracellular matrix (ECM), EC migration, and proliferation. These two latter biological processes, that 
lead to the formation of endothelial sprouts, are tightly regulated by lateral cell-cell adhesion and ECM 
interactions [6] that, in turn, are mediated by cadherin and integrin receptors. Accordingly, AGFs 
regulate EC adhesion (reviewed in [7]), and the expression of different integrins [8] and cadherins [6] 
in a complex fashion. Indeed, a brief exposure to the angiogenic FGF2 hampers endothelial cell-cell 
junctions whereas a prolonged exposure to the growth factor promotes a slow temporal re-distribution 
of junctional adhesion proteins, suggesting that AGFs promotes both EC scattering, required during 
the first steps of angiogenesis, and the formation of the cell-cell interactions necessary to vessel 
maturation [6]. A similar biphasic regulation exists also for the composition of the ECM that surrounds 
the endothelium: AGFs initially promote the disruption of the basal lamina and lately induce the 
production of appropriate ECM components by ECs [9]. The final step in angiogenesis consists in the 
so called “morphogenesis” process characterized by the organization of ECs in “capillary-like 
structures” that will mature in functional vessels. Again, this process requires the activation of the 
proteolytic machinery [10],￿ integrins [11], and junctional adhesion molecules [12] that, in turn, are 
controlled by the activity of AGFs and their tyrosine kinase (TK)-receptors [13]. 
 
 Sensors 2009, 9                  
 
 
6473
 
Figure 1. Schematic representation of the neovascularization process. Adapted from [14]. 
 
2. Surface Plasmon Resonance (SPR) Spectroscopy for the Study of the Angiogenesis Process 
A typical setup of a solid-phase bioassay based on SPR spectroscopy is shown in Figure 2. 
Polarized beam of monochromatic visible light is passed through a prism fitted with a glass slide 
coated with about 50 nm of gold (or other metal). The light is reflected off the gold and its intensity is 
detected at the specular angle. An electric field intensity, known as an evanescent wave, is generated 
when the light strikes the glass. This evanescent wave interacts with, and is absorbed by, free electron 
clouds in the gold layer, generating electron charge density waves called plasmons and causing a 
reduction in the intensity of the reflected light. The angle corresponding to the sharp intensity 
minimum that occurs at the SPR condition is called resonance angle. It depends on the refractive index 
(RI) of the material above and near (below 300 nm) the gold surface, as it is sampled by the evanescent 
light intensity. The resonance angle can be monitored by following the specularly reflected light 
intensity versus angle at fixed wavelengths or versus wavelength at fixed angle. In a SPR assay, the 
receptor specific for a particular analyte is chemically immobilized onto the gold film. When the 
sensor is exposed to a sample containing that analyte, the binding of the analyte to the receptor causes Sensors 2009, 9                  
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a change of the RI at the metal surface resulting in the shift of the resonance angle and providing label- 
free transduction of the binding reaction. Due to its peculiar architecture, SPR bioassays add to label-
free molecular recognition several advantages, including the ability to investigate and manipulate 
minute concentrations of molecules semi-automatically, in real time and multiplexed way and the 
access to information spanning from straight ON-OFF sensing to binding thermodynamics and 
kinetics. For these reasons SPR represents a powerful asset in the study of biomolecular interactions, 
including the molecular bases of angiogenesis [15–23]. 
Figure 2. Schematic representation of SPR technology. The molecule immobilized onto 
the gold film of the sensor chip is named ligand whereas the analyte is represented by the 
putative partner injected into the microfluidic system. 
 
 
As mentioned above, AGFs establish a network of extracellular interactions in order to exert their 
full angiogenic potential. Indeed, a complex molecular “interactome” due to the cross-talk among cell 
surface receptors, ECM components, and free molecules appears to modulate the angiogenic balance 
in normal and pathological settings [7]. In this context, SPR has been usefully exploited to demonstrate 
and/or characterize the binding of AGFs with their interactors, including cell surface signalling 
receptors (Table 1) and extracellular proteoglycans (Table 2).  
From the analysis of these tables it emerges that the binding parameters may vary significantly not 
only among different binding partners but also for the same interactors in different studies. These 
discrepancies may be due to suboptimal data and/or over-interpreted results [15–23]; different 
immobilization procedures of the ligand; the use of different molecular forms of the ligand and/or of 
the analyte (e.g., different receptor isoforms, different AGF variants, glycosaminoglycans (GAGs) of 
different chemical structure). See also Section 5 for a further discussion about this point. 
Beside the characterization of the direct AGF/receptor interaction, SPR has been also employed to 
measure the concentration of AGFs in body fluids. This has been successfully achieved for   
HGF [55–57] and has been proposed also for FGF2 [58]. Sensors 2009, 9                  
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Finally, different SPR-based experimental models have been set up and used for the identification 
of antiangiogenic compounds (Table 3). With these models, various promising inhibitors (including 
neutralizing antibodies directed against AGFs or their receptors) have been identified and 
characterized for their molecular mechanism(s) of action (see references in Table 3).  
 
Table 1. SPR analysis of the interaction of AGFs with their signalling receptors. SPR was 
used to assess the kinetics of interaction between the free AGF (analyte) and the extracellular 
domain of the cognate signalling receptor immobilized to the sensor chip (ligand).  
AGF Immobilized  receptor   
Binding parameters 
Reference 
Kon (M-1 s-1) Koff (s-1)  Kd (nM) 
FGF2 
 
FGFR1-IIIc (D1-D3)  
FGFR1-IIIc (D2-D3) 
FGFR1-IIIc (D2-D3) 
FGFR1-IIIc (D1-D3) 
FGFR2-IIIb  
FGFR3-IIIc (D2-D3) 
1.1 × 10
5 
9.6 × 10
4 
9.6 × 10
4 
3.0 × 10
5 
1.3 × 10
6 
No binding 
1.1 × 10
-2 
5.9 × 10
-3 
6.0 × 10
-3 
1.4 × 10
-6 
6.5 × 10
-4 
No binding 
 99.0 
 62.0 
 62.0 
 0.005 
 0.5 
No binding 
[24] 
[25]
 *
 
[26]* 
[A. Bugatti,UD] 
[27] 
[26] * 
v3 integrin receptor  5.1 × 10
4   3.3 × 10
-4   6.5  [A. Bugatti,UD]* 
FGF1  FGFR1-IIIc  
FGFR1-IIIc (D2-D3) 
FGFR1-IIIc (D2-D3) 
FGFR2-IIIb (D2-D3) 
FGFR2-IIIb  
FGFR3-IIIc (D2-D3) 
FGFR3-IIIc (D2-D3) 
FGFR3-IIIc (D1-D3) 
2.4 × 10
6  
NR 
2.2 × 10
5 
1.4 × 10
5 
8.0 × 10
5 
8.8 × 10
5  
8.8 × 10
5 
2.0 × 10
5 
4.1 × 10
-3 
NR 
3.0 × 10
-2 
4.7 × 10
-3 
6.4 × 10
-4 
2.0 × 10
-1 
2.0 × 10
-1 
1.8 × 10
-1 
 35.0 
 0.03 
 136.0 
 59.6 
 0.8 
 230.0 
 230.0 
 916.0 
[28] 
[29] 
[26]* 
[28] 
[27] 
[30] * 
[26] * 
[30] * 
v3 integrin  receptor  NR NR 1,100.0  [29] 
FGF4   FGFR1-IIIc (D2-D3) 
FGFR2-IIIb 
FGFR3-IIIc (D2-D3) 
2.6 × 10
5 
1.5 × 10
6 
No binding 
4.3 × 10
-2 
6.1 × 10
-4 
No binding 
 165.0 
 0.42 
No binding 
[26] * 
[27] 
[26] * 
VEGF-A165  
VEGF-A165  
VEGF-A165  
VEGF-A165  
VEGF-A165  
VEGF-A165  
VEGF-A165 
 
VEGF-A165  
VEGF-A165  
VEGF-A189  
VEGF-A121 
VEGF-A109 
VEGFR2/KDR 
VEGFR2/KDR 
VEGFR2/KDR 
VEGFR2/KDR 
VEGFR2/KDR 
VEGFR1/Flt 
VEGFR1/Flt 
3.6 × 10
6 
6.6 × 10
4 
8.4 × 10
4 
0.5-2.2 × 10
6 
5.7 × 10
4 
4.0 × 10
6  
5.7 × 10
5 
1.3 × 10
-4 
1.3 × 10
-5 
3.2 × 10
-5 
2.0-4.0 × 10
-4 
2.3 × 10
-6 
3.0 × 10
-5 
1.7 × 10
-5 
 0.037 
 0.19 
 0.38 
 0.2-0.6 
 0.041 
 0.007 
 0.03 
[31] 
[32] * 
[33] * 
[34] 
[A. Bugatti, UD] 
[35] 
[33] * 
Neuropilin-1 
Neuropilin-1 
Neuropilin-1 
Neuropilin-1 
Neuropilin-1 
NR 
1-10 × 10
5 
NR 
No binding 
No binding 
NR 
1.0 × 10
-2 
NR 
No binding 
No binding 
NR 
2,000.0 
NR 
No binding 
No binding 
[36] 
[37] 
[38] 
[36] 
[37] 
VEGF-C  VEGFR1/Flt 
VEGFR2/KDR 
VEGFR3 
NR 
NR 
NR 
NR 
NR 
NR 
NR 
NR 
NR 
 
[38] 
VEGF **  VEGFR1/Flt 
VEGFR2/KDR 
8.7 × 10
5 
4.2 × 10
4 
1.5 × 10
-5 
2.7 × 10
-4 
 0.017 
 6.5 
[33] * Sensors 2009, 9                  
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Table 1. Cont. 
HGF  c-MET 
c-MET 
c-MET 
c-MET 
1.2 × 10
5 
3.0 × 10
4  
NR  
NR 
1.1 × 10
-2 
6.2 × 10
-3 
NR 
NR 
 90.0 
 50.0 
NR 
NR 
[39] 
[40] * 
[40] 
[41] * 
HIV-Tat  
VEGFR2/KDR  1.7 × 10
5  1.2  × 10
-5   0.07  [A. Bugatti, UD] 
v3 integrin receptor  1.2 × 10
7  3.8  × 10
-1   32.0  [42] * 
PDGF-BB 
PDGF-BB 
PDGF-AA 
PDGF-AA  
PDGFR 
PDGFR 
PDGFR 
PDGFR 
8.3 × 10
3 
9.5 × 10
5 
1.1 × 10
5 
3.5 × 10
3 
1.2 × 10
-3 
1.5 × 10
-3 
1.5 × 10
-3 
1.6 × 10
-3 
 150.0 
 1.6 
 13.4 
 453.0 
[43] 
* studies performed by immobilizing the AGF to the sensor chip and by using the free receptor as analyte.  
** VEGF from venom gland of Taiwan habu. UD, unpublished data. NR, data not reported. 
Table 2. SPR analysis of the interaction of AGFs with extracellular proteoglycans. 
Analyses were performed by using the free AGF as analyte and by immobilizing the 
indicated proteoglycan to the sensorchip. *studies performed by immobilizing the AGF to 
the sensorchip and using the proteoglycan as analyte. When not specified, the proteoglycan 
species was not identified. CSPG, chondroitin-sulfate proteoglycan; HSPG, heparan-
sulfate proteoglycan; MK, midkine; PTN, pleiotrophin; HB-EGF, heparin-binding 
epithelial growth factor; NR data not reported.  
AGF Immobilized  proteoglycan 
Binding parameters 
Reference 
Kon (M-1 s-1)  Koff (s-1)  Kd (nM) 
FGF2 
 
agrin 
syndecan 1/4 
HSPG  
HSPG (perlecan) 
HSPG (glypican) 
1.8 × 10
5  
1.6 × 10
7 
8.5 × 10
5 
NR 
NR 
4.6 × 10
-4 
4.4 × 10
-2 
1.3 × 10
-2 
NR 
NR 
 2.5 
 2.5 
 14.7 
NR 
NR 
[44] 
[45] 
[46] 
[47]
 * 
[48] 
CSPG 
CSPG 
CSPG 
7.7 × 10
5  
1.5 × 10
5  
No binding 
2.3 × 10
-2 
2.0 × 10
-4 
No binding
 30.5 
 12.7 
No binding 
[49]  
[50]
 * 
[45] 
FGF1  HSPG (perlecan) 
HSPG (perlecan) 
NR 
NR 
NR 
NR 
NR 
NR 
[51] 
[52] 
CSPG  No binding  No binding No binding [49] 
FGF4  HSPG  1.7 × 10
5   1.5 NR  [46] 
VEGF-A165   CSPG  7.0 × 10
5   1.7 × 10
-2   24.0  [49] 
MK  CSPG 
CSPG 
8.2 × 10
4  
1.3 × 10
4 
8.9 × 10
-5 
4.8 × 10
-3 
 1.5 
 367.0 
[49] 
[45] 
HSPG (syndecan 1/4)  6.9 × 10
4   1.7 × 10
-3   25.9  [45] 
PTN  CSPG 
CSPG 
CSPG 
4.2 × 10
5  
6.6 × 10
3  
2.0 × 10
6 
7.4 × 10
-5 
3.5 × 10
-2 
2.7 × 10
-4 
 0.2 
5210.0 
 0.14 
[49] 
[45] 
[53]
 * 
HSPG   7.6 × 10
5  8.9  × 10
-3   11.9  [45] 
HB-EGF  CSPG  1.1 × 10
6   9.1 × 10
-3   10.0  [49] 
PDGF-BB 
PDGF-AA 
PDGF-AA 
HSPG 
HSPG 
2.4 × 10
5 
3.4 × 10
4  
7.8 × 10
-4
7.8 × 10
-4 
 3.0  
 23.0  [54] 
CSPG  8.5 × 10
4  2.2  × 10
-3   25.9  [50]
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Table 3. SPR-based experimental models utilized to study AGF/receptor interactions and 
to identify AGF/receptor inhibitors.  
Experimental model  AGF (references) 
AFG/receptor 
interaction 
Ligand: receptor 
Analyte: AGF 
FGF2 [24,25,27,44–46,48,49]; FGF1 [27–29,49,51,52]; 
FGF4 [26,27,46,49]; VEGF [31,34–38,49]; MK, PTN 
[45,49]; HB-EGF [49]; HGF [39,40]; HIV-Tat [A. Bugatti, 
UD]; PDGF [54] 
Ligand: AGF 
Analyte: receptor 
FGF2 [25,26,47,50]; FGF1 [26,30]; FGF4 [27]; VEGF 
[32,33]; PTN [53]; HIV-1 Tat [42]; HGF [40,41]; PDGF 
[50] 
AGF/inhibitor or 
receptor/inhibitor 
interactions 
Ligand: AGF 
Analyte: inhibitor 
FGF2 [59]; FGF4[60]; VEGF [61–68]; HIV-Tat [69,70]; 
PDGF [71] 
Ligand: inhibitor 
Analyte: AGF 
FGF1 [72,73]; FGF2 [25,59,72–75]; VEGF [72,73,76–79]; 
IL-8 [72]; PDGF [73]; HGF [73] 
Ligand: receptor 
Analyte: inhibitor 
FGF1 [80]; FGF2 [74,81,82]; VEGF [61,66,68,83–87]; 
PDGF [43]; angiopoietin [86] 
Ligand: inhibitor 
Analyte: receptor 
FGF1 [28]; FGF2 [74,88]; VEGF [89] 
competition 
experiments: inhibitor 
vs analyte 
Ligand: receptor 
Analyte: AGF 
FGF1 [80]; FGF2 [48] [A. Bugatti, UD]; VEGF [34]; HB-
EGF [49]; MK & PTN [45] 
Ligand: AGF binder 
(e.g., heparin) 
Analyte: AGF 
FGF1 [90,91]; FGF2 [72,74,90–94]; FGF8 [A. Bugatti, 
UD]; HIV-Tat [70,95]; VEGF [91,96,97]; PDGF [98] 
UD, unpublished data. 
3. Fibroblast Growth Factor-2 (FGF2) and Its Receptors 
FGF2 is a pleiotropic factor able to stimulate different cell types, including ECs, by interacting with 
specific tyrosine kinase (TK) receptors (FGFRs). The four members of the FGFR family [FGFR1 (flg), 
FGFR2 (bek), FGFR3 and FGFR4] are encoded by distinct genes and their structural variability is 
increased by alternative splicing of their RNA transcripts [99]. The extracellular portion of FGFRs 
comprises three Ig-like domains (D1, D2, and D3, with an acidic box between D1 and D2). Their 
ligand binding and specificity reside in D2, D3, and D2-D3 linker region. X-ray crystallography has 
shown that the interactions between FGF2 and D3 are of both hydrophobic and polar character 
whereas the interactions with the D2-D3 linker are mediated mainly via hydrogen bonds. At variance, 
hydrophobic interactions dominate the interface between FGF2 and D2 [100]. 
FGFR1 is expressed by ECs in vivo [101]. In vitro, ECs of different origin express FGFR1 [102] 
and, under some circumstances, FGFR2 [103], whereas the expression of FGFR3 or FGFR4 has never 
been reported in endothelium. The interactions of FGFs with FGFRs occur with high affinity 
[dissociation constant (Kd) = 10–550 pM] and trigger the activation of complex signal transduction 
pathways [104]. However it must be pointed out that, to induce a full angiogenic response, FGF2 
needs also to interact with integrin v3 [105], ganglioside GM1 [106] and HSPGs (discussed below). Sensors 2009, 9                  
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HSPGs typically consist of a core protein and of GAG chains. HSPGs are found associated to the 
surface of almost all eukariotic cells, including ECs, at concentrations ranging between 10
5-10
6 
molecules/cell. Noticeably, HSPG expression in ECs derived from the microvasculature (where the 
angiogenic process originates) is 10–15 times higher than that found in macrovascular ECs, supporting 
the role of HSPGs in neovascularization [107]. HSPGs can link to the plasma membrane through a 
hydrophobic transmembrane domain of their core protein or through a glycosyl-phosphatidylinositol 
(GPI) anchor covalently bound to the core protein. Typical transmembrane HSPGs are syndecans, the 
most represented transmembrane HSPGs in ECs [108]. Glypicans and cerebroglycan are typical GPI-
anchored HSPGs. Perlecan is instead a typical peripheral membrane HSPG [109].  
HSPGs present at the basal site of blood vessels act as receptors for basement membrane proteins. 
HSPGs present at the luminal surface of ECs [110] contribute to the anticoagulative properties of the 
vessel surface by binding proteases of the intrinsic coagulation cascade [111] and act as receptors or 
co-receptors for a variety of cytokines and growth factors, including FGF2. Usually the binding of 
these proteins to HSPGs occurs via their GAG-chains (discussed below). 
HSPGs exist also in free form following their mobilization from cell-surface or ECMs by 
proteolytic digestion of their core protein (for transmembrane HSPGs) or by the action of 
phospholipase (for GPI-anchored HSPGs). Also, free GAGs can be generated by enzymatic digestion 
of HSPGs GAG-chain (reviewed in [112]). The biological consequences of HSPGs/FGF2 interaction 
are manifold: FGF2 binding to EC-surface HSPG promotes angiogenesis in vitro and in vivo [113] by 
direct activation of intracellular signalling [113], by mediating FGF2 internalization [114], and/or by 
presenting FGF2 to FGFRs in a proper conformation [112]. Also, ECM-associated HSPGs act as a 
reservoir for FGF2 that is protected from degradation [115] and accumulates in the microenvironment 
to sustain a long-term stimulation of ECs [116] (Figure 3). 
Figure 3. Schematic representation of the biological functions of HSPGs in FGF2 biology. 
 
 
GAGs are negatively charged polysaccharides composed of repeating disaccharide units whose 
prototype is heparin. Heparin is a natural polysaccharide produced by mast cells. Once released, it 
regulates coagulation through the binding to coagulation factors such as antithrombin III and heparin Sensors 2009, 9                  
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cofactor II [117]. Also, like HSPGs, heparin binds to a variety of enzymes, cytokines and growth 
factors, including FGF2 [118]. This capacity, that depends on distinct chemical properties of the 
polysaccharide chains, can be exploited to design heparin-like drugs for pharmacological interventions 
in a variety of pathologic conditions including thrombosis, neoplasia and viral infection [94].  
The interaction of heparin/HSPGs with FGF2 occurs with a Kd equal to 2–200 nM. Both heparin 
and GAGs/HSPGs from ECs bind FGF2 and protect it from inactivation and proteolytic   
degradation [119,120]. Also, free GAGs favour the delivery of FGF2 to the blood supply to stimulate 
angiogenesis by increasing the radius of diffusion of the growth factor [121]. Depending on its 
concentration, free heparin can act as a FGF2 agonist, inducing oligomerization of FGF2 [122] that is 
required for its full biological response [123], or as a FGF2 antagonist, sequestering FGF2 in the 
extracellular environment, hampering its interaction with ECs and inhibiting its biological   
activity [115]. 
Heparin and HSPGs can interact also with FGFRs. Indeed, heparin/HSPGs, FGF2 and FGFR1 form 
a ternary complex in which the GAG chain interacts with both FGF2 and FGFR [124]. The formation 
of the HSPG/FGF2/FGFR1 ternary complex plays a central role in the biology of FGF2 and in the 
process of neovascularization. For this reason, it has been considered as a model for the development 
of angiogenesis-related assays and a target for the development of antiangiogenic compounds. To this 
purpose, a FGF2-dependent cell-cell adhesion (CCA) assay has been developed [125] and successfully 
exploited [94,126,127] for the identification of compounds able to disrupt the HSPG/FGF2/FGFR1 
ternary complex, thus acting as angiogenesis inhibitors (Figure 4).  
Figure 4. Schematic representation of the FGF2-mediated cell-cell adhesion model. 
HSPG-bearing CHO (HSPG/CHO) cells are seeded, allowed to reach confluence and 
incubated with or without FGF2.  Next,  FGFR1-bearing CHO (FGFR1/CHO) cells are 
incubated onto the HSPG/CHO cell monolayers. Finally, FGFR1/CHO cells adherent to 
the HSPG/CHO cell monolayers are counted under the microscope. 
 
 
In this model, FGF2 mediates the interaction of HSPG-deficient CHO cells overexpressing FGFR1 
to a monolayer of CHO cells expressing HSPGs but not FGFRs [128]. As a consequence of its 
capacity to interact with any of the three molecular partners involved in the interaction, the putative Sensors 2009, 9                  
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inhibitor is anticipated to prevent the formation of the HSPG/FGF2/FGFR1 ternary complex resulting 
from the simultaneous binding of FGF2 to HSPGs and FGFR1 expressed on neighbouring cells.  
4. Extracellular FGF2 Antagonists: Exploiting SPR for the Identification of Antiangiogenic 
Compounds  
FGF2 interacts with several partners that modulate its bioavailability, stability, local concentration 
and interaction with EC [129]. On the other hand, several molecules of the body fluids or of the ECM 
interact with the various FGF2 receptors expressed on the surface of ECs. The identification of these 
molecules and the characterization of their interactions with FGF2 or with FGF2 receptors may allow 
the design of efficient and specific inhibitors. Two main categories of FGF2-antagonists have been to 
date identified: proteins of the body fluids/ECM and related peptides; polyanionic, heparin-like 
compounds (for a review see [130]). The current approaches for the identification of FGF2 antagonists 
endowed with antiangiogenic capacity are based on the screening of large libraries of compounds. 
However, the available in vitro and in vivo experimental models for testing these compounds may be 
quite complex, time-consuming and expensive, calling for additional models overcoming these 
drawbacks. SPR assays may fit these requirements, being handy-user, reliable, and high-throughput. 
4.1. Anti-FGF2 Peptides 
Several ECM components, their degradation products or related synthetic peptides affect FGF-
driven angiogenesis. Thrombospondins (TSP) are modular glycoprotein secreted by ECs that bind to 
HSPGs and integrin receptors [131]. TSP-1 exerts an antiangiogenic effect that is due, at least in part, 
to its capacity to bind FGF2 [132], preventing its interaction with HSPGs and FGFRs and inhibiting its 
mitogenic and chemotactic activity on ECs. TSP-1 also prevents FGF2 accumulation in the ECM and 
favors matrix-bound FGF2 mobilization, generating inactive TSP-1/FGF2 complexes [133]. Fibstatin 
is a fibronectin fragment that binds FGF2 and inhibits FGF2-dependent proliferation, migration and 
tubulogenesis of ECs in vitro and angiogenesis and tumor growth in vivo [134].  
A variety of serum components can bind and regulate FGF2. 2-Macroglobulin (2M) is a plasma 
protein that acts as a protease inhibitor and binds a variety of cytokines and growth factors [135]. 2M 
sequesters FGF2 in the extracellular environment inhibiting its cell interaction, protease-inducing 
activity [136], and mitogenic capacity [135]. Pentraxin 3 (PTX3) is a soluble pattern recognition 
receptor with unique functions in various physio-pathological conditions released by mononuclear 
phagocytes and ECs [137]. Its functions relay on its capacity to bind different molecules, including 
FGF2 [138]. PTX3 prevents the binding of FGF2 to EC surface FGFRs, inhibits EC proliferation and 
migration, and FGF2-dependent neovascularization and tumorigenesis in vivo [138]. PDGF-BB [139], 
PF4 [140], CXCL13 [141] bind FGF2, inhibiting its interaction with HSPGs and FGFR1, FGF2 
internalization, mitogenic and/or anti-apoptotic activity of cultured ECs and angiogenesis in vivo.  
Several peptides derived from FGF2, FGFRs or the natural FGF2-binders described above have 
been demonstrated to exert an inhibitory activity on the FGF2/FGFR system (Table 4). Among the 
more than 80 FGF2 antagonist peptides so far described, only a few of them have been identify or Sensors 2009, 9                  
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characterized by SPR analysis. Nevertheless, these studies show the potentiality of this technology for 
a systematic identification of FGF2 inhibitors. 
Table 4. Synthetic peptides endowed with FGF2-antagonist capacity. 
Protein of origin  Peptides  Target  References 
FGF2 
 
 
 
 
 
 
 
 
 
 
FGF2(48–58) (FREG)  FGF2  [142] 
FGF2(38–61) ?  [143] 
FGF2(82–101) ?  [143] 
FGF2(119–126) FGF2  [74]* 
FGF2-derived DGR-containing peptides (4 peptides studied)  ?  [143] 
FGF2(68–77) FGFR  [144] 
FGF2(24–68) (Peptide D)  FGFR   [145,146] 
FGF2(93–120) (Peptide N)  FGFR  [145] 
FGF2(106–115) FGFR    [145,146] 
FGF2(103–146) FGFR  [147] 
F2A4-K-NS   FGFR  [24] 
FGFs (10-11 loop)   dekafins (homologous to the NCAM FGFR-binding region)  FGFR  [28]* 
FGF1 
 
 
FGF1(112–147) and related peptides  FGFR  [148] 
FGF1(99–108) FGFR  [149] 
FGF1 mimetics (6 peptides studied)  FGFR  [150] 
FGF5   FGF5(95–104) (peptide P3)  FGFR  [151] 
N-cadherin   EDC4 mimetics (2 peptides studied)  FGFR  [150] 
PTX3 N-terminus  PTX3(97–110) (and 28 related peptides)  FGF2  [92]* 
PF4  PF4(47-70)  FGF2 [152] 
Myelin Basic Protein   MBP(152–167) FGFR  [153] 
TSP-1 
 
4N1K ?  [154] 
(type III repeats-derived peptides) (6 peptides studied)  FGF2  [59]* 
NCAM(681-695) 
 
 
 
 
 
 
 
 
FGL FGFR  [155-158] 
FRM-10 FGFR  [156,158,159]
FRM-10 cyclic  FGFR  [156,158,159]
FRM-13 FGFR  [156,158,159]
DekaCAM FGFR  [28,156,158] 
BCL FGFR  [156,158,160]
Encamin A  FGFR  [156,161] 
Encamin C  FGFR  [156,161] 
Encamin E  FGFR  [156,161] 
Random phage 
epitope library 
screening  
 
 
 
Epitope sequence  FGFR  [162] 
FGF2(13–18) FGFR  [162] 
FGF2(119–126) FGFR  [162] 
FGF2(120–125) FGFR  [162] 
Peptide P7 (hydrophobic)  FGF2  [163] 
C19 (3 peptides studied)  FGFR  [164–166] 
Peptide P2 (hydrophobic)  FGFR  [167] 
Molecular modelling  16–24 mer peptides   FGFR  [82,168]*  
?: target and/or mechanism of action not characterized. * studied by SPR. Sensors 2009, 9                  
 
 
6482
 
Regarding peptides that bind and sequester FGF2, SPR has been exploited to demonstrate that the 
FGF2-derived peptide KRTGQYKLC inhibits FGF2/FGFR1 interaction by binding to FGF2 itself 
rather than to FGFR [74].  
Regarding peptides that bind and mask FGF2 receptors, a 16-mer oligopeptide with no sequence 
homology to FGF2 but endowed with conformational similarity to its putative receptor-binding 
domain was demonstrated to effectively bind to FGFR1 immobilized to a SPR sensorchip [82]. Also, 
the high-through-put feature of SPR allowed a systematic study of the binding of up to 10 FGF-derived 
peptides (named dekafins) to the D2-D3 domain of both FGFR1-IIIc and FGFR2-IIIb [28]. Also, SPR 
has been used to demonstrate that endostatin binds to HSPGs, suggesting its angiostatic activity may 
depend, at least in part, on its capacity to mask these receptor to FGF2 [81]. Finally, SPR has been 
used to analyze large panels of TSP-derived [59] or PTX3-derived peptides [92]. 
Figure 5. FGF2-antagonist activity of PTX3-derived peptides. A)  Schematic 
representation of the peptides (in grey) spanning the N-terminal domain of PTX3 utilized 
for the identification of the amino acid sequence 97–110 as the FGF2-binding domain in 
PTX3 [92]. The synthetic peptides based on the PTX3(97–110) sequence and used for the 
analysis shown in panel B are reported in black. B) Relationship between the potency of 
the peptides to inhibit FGF2/FGFR1-IIIc interaction in a SPR assay and 
HSPG/FGF2/FGFR1 ternary complex formation in a FGF2-dependent CCA assay 
[expressed as the concentration of peptide required to obtain 50% inhibition (ID50)]. (Data 
from both the assays were the mean of three independent experiments, performed in 
duplicate for CCA assay).  
 
 
In our previous work, by assaying a large panel of synthetic peptides encompassing the N-terminal 
extension of human PTX3 we were able to identify the FGF2-binding domain of PTX3 in the amino 
acid sequence 97–110 [92,138]. More recently, a series of synthetic peptides based on amino acid 
sequence PTX3(97–110) and containing different mutations in the Ala-Arg-Pro-Cys-Ala (ARPCA) 
motif (Figure 5A) were assessed for their FGF2-binding and antiangiogenic activity in vitro and in Sensors 2009, 9                  
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vivo [169]. As a preliminary experiment, the peptides were tested for their capacity to prevent the 
binding of FGF2 to FGFR1-IIIc (D1-D3) immobilized to a SPR sensorchip. Interestingly, a significant 
correlation was found between the capacity of these peptides to inhibit FGF2/FGFR1-IIIc interaction 
in the SPR-based assay and their ability to prevent the formation of a productive HSPG/FGF2/FGFR1 
ternary complex in the FGF2-dependent cell-cell adhesion assay described above (Figure 5B). 
4.2. Anti-FGF2 Polyanionic Heparin-Like Molecules 
Free heparin sequesters FGF2 in the extracellular environment, thus exerting an antiangiogenic 
effect. However, mainly due to its anticoagulant activity and binding aspecificity, unmodified heparin 
cannot be used as an antiangiogenic drug [127]. This started a series of researches aimed at identifying 
non-anticoagulant heparin analogous and polyanionic compounds endowed with a more specific FGF2 
antagonist activity (reviewed in [7,130,170]). In this context, our laboratory has been involved in the 
study of a powerful and versatile class of heparin-like molecules originated by chemical and enzymatic  
modifications of the polysaccharide K5 (reviewed in [171]). K5 is produced by E. coli and has the 
same structure of the biosynthetic precursor of heparin/HS. This allows the chemical synthesis of 
novel heparin-like K5 derivatives characterized by different patterns of sulfation and chemical 
structure and endowed with a significant antiangiogenic capacity but devoid of anticoagulant a 
ctivity [172]. 
On this basis, we decided to assess whether SPR screening of K5 derivative/FGF2 binding might 
provide a valuable hint for structure-function correlation studies and might have a predictive value for 
the antiangiogenic potential of the heparin-like compound under test. To this purpose, in a first set of 
experiments we immobilized FGF2 to a SPR sensorchip and we used this assay to evaluate the 
individual binding capacity to FGF2 of a large panel of K5 derivatives differing for sulfation degree 
and chemical structure. Binding to FGF2 occurs through the negatively charged sulfated groups of the 
GAG [112]. Accordingly, we found a significant correlation between the degree of sulfation of K5 
derivatives [expressed as sulfate/carboxyl group (S/C) ratio] and their capacity to bind FGF2 
immobilized to the sensorchip [measured as the amount of K5 derivative that binds surface-
immobilized FGF2 at the equilibrium] (Figure 6).  
It is worth noticing that we intentionally avoided using in this analysis the binding affinities 
evaluated from the SPR data. The reason is that the state-of-the-art physicochemical models available 
for their evaluation rely on the approximations of bimolecular interactions described by the Scatchard's 
equation [173,174] that are definitively too tight for the molecular system under evaluation. Indeed, 
the specific binding to FGF2 dependents not only on the overall sulfation degree of GAGs but also on 
the presence and number of definite sequences of sulfated groups within their backbone structure and 
may involve mechanisms of cooperative interaction [175]. This point reflects a pivotal basic aspect of 
the discussion about reliability and accuracy of binding parameters evaluated by SPR (and by solid-
phase bioassays in general) and about their actual or presumed difference with the parameters 
evaluated in free solution and in cell-based assays (see below for a further discussion about this   
crucial point). Sensors 2009, 9                  
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In a second set of experiments, the K5 derivatives were assayed for their capacity to prevent the 
formation of a productive HSPG/FGF2/FGFR1 ternary complex in the FGF2-dependent cell-cell 
adhesion assay described above. Although with low statistical significance, a correlation trend appears 
to exist between the capacity of K5 derivatives to inhibit FGF2-dependent HSPG/FGF2/FGFR1 
ternary complex formation and their ability to bind immobilized FGF2 (Figure 7). 
Figure 6. SPR runs of FGF2/K5 derivative interaction.  FGF2 was immobilized to a 
sensorchip as described in  [133]. Immobilized BSA was used as control and for blank 
subtraction. The various K5 derivatives (30 nM) were injected onto the FGF2- or BSA-
coated sensor chips for four minutes and washed until full dissociation. After each run, the 
sensor chips were regenerated by a 2 M NaCl pulse [133]. A) Blank-subtracted sensorgram 
overlay showing the binding of K5 derivatives to sensorchip-immobilized FGF2. B) Plot of 
the blank-subtracted values of the SPR response at equilibrium for equimolar concentrations 
of each K5 derivative versus  its sulfate/carboxyl (S/C) ratio. The SPR responses at 
equilibrium are taken from a single experiment out of three giving consistent results. 
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Figure 7. Correlation between SPR-generated binding parameters for the interaction of 
FGF2 with K5 derivatives and their antiangiogenic potential. SPR response at equilibrium 
of K5 derivatives to immobilized FGF2 were plotted versus the capacity of the FGF2 
antagonist to inhibit HSPG/FGF2/FGFR1 ternary complex formation in the FGF2-
dependent CCA assay (expressed as % of inhibition when the compounds were tested at 
the dose of 10 g/mL). The data from CCA assays are the mean value from three different 
experiments performed in duplicate. The SPR responses at equilibrium are taken from a 
single experiment out of three giving consistent results. 
 
These data support the hypothesis that SPR-generated parameters obtained from the analysis of the 
direct interaction of FGF2 with heparin-like polyanionic compounds may provide useful hints about 
the structure/function relationship of FGF2 antagonists. However, as shown in Figure 7, it is apparent 
that some K5 derivatives endowed with a very similar FGF2-binding capacity may show a quite 
different ability to prevent HSPG/FGF2/FGFR1 ternary complex formation and vice versa. This may 
be due to the capacity of some K5 derivatives to interfere directly with FGF2/FGFR1 interaction rather 
than with FGF2/HSPG interaction, calling for additional SPR experiments with sensorchip-
immobilized FGFR1 (see Figure 5). 
As described above, FGF2 binds to HSPGs anchored to the surface of ECs. In order to more closely 
mimic the biological environment in which FGF2 antagonists may act, we exploited a second SPR 
experimental model in which heparin was immobilized to a SPR sensorchip and FGF2 was used as an 
analyte were performed [94]. FGF2 binds to immobilized heparin in a specific (Figure 8A) and dose-
dependent manner (data not shown). Evaluation of the kinetic parameters of the interaction revealed 
that this occurs with parameters [Kon = 9.0 × 10
3 M
-1 s
-1, Koff = 3.8 × 10
-4 s
-1, Kd = 42.5 nM] [94], 
consistent with previous measurements of the affinity of interaction of FGF2 with EC-associated 
HSPGs [112] (see also Table 2), further validating SPR analysis as a surrogate model for more 
classical cell culture-binding experiments. The binding of FGF2 to immobilized heparin was inhibited 
when the growth factor was co-injected on the sensorchip in the presence of increasing concentrations 
of free heparin (Figure 8B), thus confirming the possibility to use this SPR-based assay for the 
screening of polyanionic heparin-like FGF2 antagonists. Sensors 2009, 9                  
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Figure 8. Capacity of LMW-K5 derivatives to prevent FGF2/heparin interaction in a SPR-
based assay A)  Heparin was biotinylated  at its reducing end and immobilized onto a 
sensorchip previously activated with streptavidin. A streptavidin-activated sensorchip 
without biotinylated heparin was used as a negative control. FGF2 (260 nM) was injected 
over heparin-coated (straight lane) and control (dotted lane) sensor chips for four minutes 
and washed until dissociation was observed. After each run, the sensor chips were 
regenerated by a 2 M NaCl pulse. For further details see [94]. The response (in RU) was 
recorded as a function of time. Adapted from [94]. B) Sensorgram overlay showing the 
binding of FGF2 to immobilized heparin in the presence of increasing concentrations of 
free heparin. C) Different LMW-K5 derivatives were evaluated for their capacity to inhibit 
FGF2/heparin interaction in the SPR assay (expressed as % of inhibition when the 
compounds were tested at the dose of 300 nM) and to prevent HSPG/FGF2/FGFR1 ternary 
complex formation in the FGF2-dependent CCA assay (expressed as % of inhibition when 
the compounds were tested at the dose of 200 nM). Data from both CCA and SPR assays 
were the mean of three independent experiments (performed in duplicate for CCA assay). 
 
 
 
On this basis, a series of low molecular weight (LMW) K5 derivatives were evaluated for their 
capacity to prevent the binding of FGF2 to immobilized heparin and the SPR-generated data were 
compared to the data obtained when the same compounds were tested for the capacity to inhibit the 
formation of the HSPG/FGF2/FGFR1 ternary complex in the cell-cell adhesion assay described above. Sensors 2009, 9                  
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A clear correlation, exists between the results provided by the two assays (Figure 8C). This is in fair 
agreement with the results shown in Figure 7, further supporting the possibility to use SPR-based 
assays for the screening of polyanionic heparin-like FGF2 antagonists. 
Interestingly, a similar correlation was found also when the SPR-generated data were challenged 
against the results obtained when the LMW-K5 derivatives were evaluated for their capacity to inhibit 
FGF2-dependent EC proliferation and sprouting, two widely diffused angiogenesis-related assays (for 
further details, see [94]). Finally, those compounds that turned out to be efficient FGF2 antagonists in 
the SPR assay showed a significant capacity to inhibit FGF2-angiogenesis in vivo in the chick embryo 
chorionallantoic membrane model [94]. These observations strongly support the exploitation of SPR 
measurements as a first-lane screening predictive of antiangiogenic activity. 
The identification of lead compound(s) from a large library is only the first step in the development 
of effective antiangiogenic drugs. Indeed, lead compounds must be properly modified to increase their 
efficiency, specificity and safety. Also, this phase of the research calls for affordable and reliable 
systems that allow the real-time monitoring of the structure-function modifications.  
5. Understanding the Surface-Confined Molecular Recognition: towards an Integrated 
Biosensing Strategy 
As introduced in Section 2, SPR has been exploited to demonstrate and/or characterize the binding 
of AGFs with their interactors. However, as it emerges from Table 1 and 2, evaluation of kinetic and 
thermodynamic parameters by SPR experiments and data from different laboratories often provide 
significantly different results. According to the revised literature this may origin from various 
“biosensing” as well as “molecular” reasons, including: 
i) suboptimal data and/or over-interpreted results. A long list of these flaws, that are outside the 
target of this review, has been reported in details in the survey of commercial optical biosensor 
literature series [15–23]. It is important to note that a broad and detailed array of “guidelines” for the 
interpretation of SPR results is reported in these reviews. If correctly applied, these guidelines would 
reduce by a great extent the misinterpretations of SPR data, with great benefits for SPR studies in 
general and angiogenesis in particular.  
ii) “lead up” or “lead down” experiments (e.g., the alternative choice to immobilize the AGF or its 
receptor onto the sensorchip surface). According to the state-of-the-art theory, the alternative choice of 
immobilization should lead to the same binding parameters. However, many “immobilization-driven” 
artefacts may affect the binding results under the different experimental conditions. Among them, 
mass transport effect may greatly (and differently) impact the lead up or lead down experiments. The 
comparison among binding data obtained at the solid-solution interface and in bulk solution may 
provide a valuable help in the interpretation of the results.  
iii) different immobilization procedures that can mask or alter the accessibility of binding sites 
present in the ligand molecule; 
iv) the use of different molecular forms of the ligand and/or of the analyte (e.g., different receptor 
isoforms, different AGF variants, GAGs of different chemical structure and charge). Sensors 2009, 9                  
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Focusing on the “biosensing” issues, two intertwined actions are desirable in order to take a full 
advantage of SPR and other biosensor-based technologies for a better understanding of the molecular 
interactions during the angiogenesis process, as well as in other biological processes. From one hand, 
integrated approaches grounded on the combination of different biosensing techniques based on 
complementary transduction principles should be implemented. On the other hand, a deeper 
knowledge of ligand-receptor interactions confined at solid-solution interfaces may provide the basis 
for a better understanding of those interactions occurring at the (subtler) biological interfaces. 
SPR spectroscopy ultimately relies on measuring the variation of the RI at the solid-solution 
interface that hosts the recognition event. However, any species adsorbed at the interface within few 
hundreds of nanometers can sort a variation of the RI and in turn generate a detection signal. 
Therefore, interpretation of SPR data might result problematic under not well-controlled conditions, as 
it is the case for non-specific adsorption, ligand-induced conformational changes, or multimeric and 
allosteric interactions. Also, SPR might present difficulties when utilized with low molecular weight 
analytes, since binding might not sort a measurable RI change. To overcome these problems, SPR 
experiments might be complemented by replicate experiments performed with label-free biosensors 
that feature alternative transduction mechanisms, such as quartz crystal microbalances that feature 
mass-based transduction, nanomechanical microcantilevers that feature mass- or energy-based 
transduction, electrochemical impedance spectroscopy, or isothermal titration (nano)calorimetry. All 
of these alternative techniques present advantages as well as drawbacks with respect to SPR.  
Integration of different biosensors [176] will be more effective when an adequate understanding and 
control of ligand-receptor interactions confined at solid-solution interfaces and of the confining 
environment (including immobilization of the biomolecules onto the solid-phase) will be achieved On 
this subject, research is at the beginning and the literature somehow contradictory, pointing to 
substantial [176] or negligible [17,19] thermodynamic difference between the two systems. Basically, 
“surface effects” are recognized and qualitative caveat and solutions have been proposed. A 
throughout, updated, guideline for good practices can be found in the above cited reviews about 
commercial optical biosensor literature [15–23], in ref. [177] and, generally, in the application-notes 
supplied by the instrument dealers. 
An alternative, promising evolution path is marked down by the development of a thermodynamic 
framework able to accurately describe ligand-receptor interactions confined at solid-solution   
interfaces [178,179].  
6. Conclusions 
Angiogenesis is the process of generating new capillary blood
  vessels. Uncontrolled 
neovascularization is observed in tumor growth and in angioproliferative diseases [2].
 Tumors cannot 
grow larger than a few square millimetres
 as a mass unless a new blood supply is induced [1]. Hence 
the
 control of the neovascularization process may affect tumor growth
 and represent a novel approach 
to angiogenesis-dependent disease therapy, including neoplasia [180]. A complex molecular 
“interactome” due to the cross-talk among cell surface receptors, ECM components, and free AGFs Sensors 2009, 9                  
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appears to modulate the angiogenic balance in normal and pathological settings [7]. In this context, 
SPR can be usefully exploited to demonstrate and/or characterize the interaction of AGFs with their 
interactors and for the screening and characterization of antiangiogenic compounds. 
SPR is a widely used powerful technology to study macromolecular interaction. Originally released 
in 1991, it has been used and cited in up to 10,000 papers in the last 12 years. Nevertheless, SPR has 
been sparingly employed in the study of angiogenesis-related molecules. In effect, a PubMed search on 
SPR and angiogenesis yielded only 80 papers (published from 1993 to date), 50% of them being 
devoted to the study of the molecular bases of the interaction of angiogenic growth factors with their 
receptors and the remaining ones to the exploitation of SPR for the identification of antiangiogenic 
compounds. Thus, the full potential of SPR in the study of angiogenesis remains largely unexploited.  
Here, using the FGF2/FGFR1 system as a prototypic angiogenesis-related target, we have 
evidenced how SPR-based assays can be successfully used in the search and development of 
antiangiogenic compounds belonging to different classes of compounds, like synthetic peptides and 
heparin-like molecules.  
It must be pointed out that human tumors in advanced stages of growth, usually characterized by a 
high degree of vascularization, may express various AGFs, suggesting that tumor neovascularization 
may represent the result of the simultaneous action of different AGFs [181]. Therefore, “multivalent” 
compounds (able to bind different AGFs) may be highly effective in inhibiting angiogenesis and tumor 
progression in vivo. Relevant to this point, several AGFs are endowed with heparin-binding capacity 
and must interact with HSPGs receptors to exert their full angiogenic potential [7]. To this respect, 
SPR-based assays may be of great advantage. Large libraries of putative HSPGs-antagonist can be 
easily and rapidly screened against a panel of heparin-binding AGFs in search of possible multitarget 
compounds able to inhibit simultaneously the interaction of different AGFs with heparin/HSPGs 
immobilized to the sensorchip (Table 5).  
Table 5. Polyanionic heparin-like compounds investigated by SPR for their capacity to 
inhibit the binding of AGFs to heparin immobilized to the sensorchip.  
Heparin-like compounds  AGF  Reference 
K5 derivatives  
suramin analogs 
FGF2 
[94] 
[M. Presta, UD] 
K5 derivatives   FGF8 [M.  Presta,  UD] 
Glycol-split heparins  
phosphosulfomannan derivatives  
VEGF 
[96] 
[97] 
pentosan polysulfate 
sulfonic acid polymers 
K5 derivatives  
HIV-Tat 
[95] 
[70] 
[A. Bugatti, UD] 
partially digested CS* HB-EGF  [49] 
* Tested on immobilized CS. UD, unpublished data. Sensors 2009, 9                  
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Relevant to this point, SPR has been already exploited for the screening of large libraries of 
polyanionic compounds directed against FGF2 and FGF1 [93,182] or against a panel of up to 6–10 
different heparin-binding cytokines [72,73]. 
A deeper understanding of ligand-receptor interactions supported by solid-phase assays and the 
integrated use of label-free biosensors based on complementary transduction principles will greatly 
improve our comprehension of the molecular interactions occurring during the angiogenesis process, 
paving the road for the discovery of novel antiangiogenic drugs. 
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